Transforming Cancer Care Through Precision
Personalized Insights for Targeted Cancer Treatment
Conventional and molecular cytogenetics are essential tools for detecting chromosomal
abnormalities in genetic disorders, cancers, and prenatal conditions. Conventional
karyotyping visualises entire chromosomes, identifying structural rearrangements,
aneuploidies, and large deletions. Fluorescence in situ hybridisation (FISH) adds higher
resolution, targeting specific genes or regions for rapid, precise detection. Molecular
cytogenetic techniques, such as array comparative genomic hybridisation (aCGH) and
chromosomal microarray analysis (CMA), uncover submicroscopic copy number
variations missed by traditional methods. Together, these approaches provide
comprehensive genomic insights, guiding accurate diagnosis, prognosis, and therapeutic
decisions. CMDL integrates both methodologies to ensure clinicians receive detailed,
actionable data for personalised patient management.
